Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
| Autor: | Hans Petersen, Anand A. Dalal, Kathy Manavi-Zieverink, Christopher M. Blanchette, Meaghan St Charles, Melissa H. Roberts |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty economic Exacerbation Combination therapy Cost effectiveness Cost-Benefit Analysis maintenance therapy International Journal of Chronic Obstructive Pulmonary Disease Severity of Illness Index law.invention Pulmonary Disease Chronic Obstructive Maintenance therapy Randomized controlled trial law Internal medicine Medicine COPD Humans Albuterol Salmeterol Xinafoate Fluticasone Original Research Aged Randomized Controlled Trials as Topic business.industry cost-effectiveness analysis General Medicine Middle Aged medicine.disease Fluticasone-Salmeterol Drug Combination Bronchodilator Agents respiratory tract diseases Androstadienes Drug Combinations Physical therapy Drug Therapy Combination Female Salmeterol business medicine.drug |
| Zdroj: | International Journal of Chronic Obstructive Pulmonary Disease |
| ISSN: | 1178-2005 |
| Popis: | Anand A Dalal1, Meaghan St Charles2, Hans V Petersen2, Melissa H Roberts2, Christopher M Blanchette2, Kathy Manavi-Zieverink31US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, 2Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis USA; 3INC Research, Raleigh; NC, USAObjective: To estimate the cost-effectiveness of fluticasone propionate–salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD).Study design: Pooled economic analysis.Methods: We performed an economic analysis of pooled data from two randomized clinical trials (combined N = 1554) that evaluated the effect of maintenance therapy with FSC (250/50 μg twice daily) or salmeterol (50 μg twice daily) on exacerbation rates in patients with severe COPD. We calculated exacerbation rates and applied standardized costs to exacerbation-related health care utilization reported in the trials (office, urgent care, and emergency department visits; hospitalizations; and oral corticosteroids and antibiotics) to determine cost differences between FSC and salmeterol treatment outcomes.Results: Annual rates of any exacerbation and moderate/severe exacerbation were lower in the FSC group than the salmeterol group (4.91 vs 5.78 and 1.32 vs 2.00 respectively, both P < 0.05). Total adjusted annual COPD related exacerbation and therapeutic costs were $4,842 (95% CI; $4,731–$4,952) in the FSC group and $5,066 (95% CI; $4,937–$5,195) in the salmeterol group.Conclusions: FSC combination therapy is associated with reduced risk of any exacerbation and moderate/severe exacerbation, and incurs lower annual COPD-related health care costs compared to treatment with salmeterol. This analysis demonstrates that FSC therapy may be advantageous from both a clinical and cost-benefit standpoint for patients with severe COPD.Keywords: COPD, cost-effectiveness analysis, economic, maintenance therapy |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|